An update on SARS-CoV-2 immunization and future directions

Millions of people have died as a result of SARS-CoV-2, which was first discovered in China and has since spread globally. Patients with SARS-CoV-2 infection may show a range of symptoms, including fever, coughing, and shortness of breath, or they may show no symptoms at all. To treat COVID-19 sympt...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 14; p. 1125305
Main Authors Rana, Rashmi, Kant, Ravi, Kumra, Tanya, Gupta, Sneha, Rana, Devinder Singh, Ganguly, Nirmal Kumar
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 09.03.2023
Subjects
convalescent plasma therapy
COVID-19
herd immunity
Pharmacology
reinfection
SARS-CoV-2
vaccine efficacy
COVID-19
herd immunity
convalescent plasma therapy
SARS-CoV-2
reinfection
Pfizer
Moderna
vaccine efficacy
Online AccessGet full text

Cover

Abstract Millions of people have died as a result of SARS-CoV-2, which was first discovered in China and has since spread globally. Patients with SARS-CoV-2 infection may show a range of symptoms, including fever, coughing, and shortness of breath, or they may show no symptoms at all. To treat COVID-19 symptoms and avoid serious infections, many medications and vaccinations have been employed. However, to entirely eradicate COVID-19 from the world, next-generation vaccine research is required because of the devastating consequences it is having for humanity and every nation’s economy. Scientists are working hard to eradicate this dangerous virus across the world. SARS-CoV-2 has also undergone significant mutation, leading to distinct viral types such as the alpha, beta, gamma, delta, and omicron variants. This has sparked discussion about the effectiveness of current vaccines for the newly formed variants. A proper comparison of these vaccinations is required to compare their efficacy as the number of people immunized against SARS-CoV-2 globally increases. Population-level statistics evaluating the capacity of these vaccines to reduce infection are therefore being developed. In this paper, we analyze the many vaccines on the market in terms of their production process, price, dosage needed, and efficacy. This article also discusses the challenges of achieving herd immunity, the likelihood of reinfection, and the importance of convalescent plasma therapy in reducing infection.
AbstractList Millions of people have died as a result of SARS-CoV-2, which was first discovered in China and has since spread globally. Patients with SARS-CoV-2 infection may show a range of symptoms, including fever, coughing, and shortness of breath, or they may show no symptoms at all. To treat COVID-19 symptoms and avoid serious infections, many medications and vaccinations have been employed. However, to entirely eradicate COVID-19 from the world, next-generation vaccine research is required because of the devastating consequences it is having for humanity and every nation's economy. Scientists are working hard to eradicate this dangerous virus across the world. SARS-CoV-2 has also undergone significant mutation, leading to distinct viral types such as the alpha, beta, gamma, delta, and omicron variants. This has sparked discussion about the effectiveness of current vaccines for the newly formed variants. A proper comparison of these vaccinations is required to compare their efficacy as the number of people immunized against SARS-CoV-2 globally increases. Population-level statistics evaluating the capacity of these vaccines to reduce infection are therefore being developed. In this paper, we analyze the many vaccines on the market in terms of their production process, price, dosage needed, and efficacy. This article also discusses the challenges of achieving herd immunity, the likelihood of reinfection, and the importance of convalescent plasma therapy in reducing infection.Millions of people have died as a result of SARS-CoV-2, which was first discovered in China and has since spread globally. Patients with SARS-CoV-2 infection may show a range of symptoms, including fever, coughing, and shortness of breath, or they may show no symptoms at all. To treat COVID-19 symptoms and avoid serious infections, many medications and vaccinations have been employed. However, to entirely eradicate COVID-19 from the world, next-generation vaccine research is required because of the devastating consequences it is having for humanity and every nation's economy. Scientists are working hard to eradicate this dangerous virus across the world. SARS-CoV-2 has also undergone significant mutation, leading to distinct viral types such as the alpha, beta, gamma, delta, and omicron variants. This has sparked discussion about the effectiveness of current vaccines for the newly formed variants. A proper comparison of these vaccinations is required to compare their efficacy as the number of people immunized against SARS-CoV-2 globally increases. Population-level statistics evaluating the capacity of these vaccines to reduce infection are therefore being developed. In this paper, we analyze the many vaccines on the market in terms of their production process, price, dosage needed, and efficacy. This article also discusses the challenges of achieving herd immunity, the likelihood of reinfection, and the importance of convalescent plasma therapy in reducing infection.
Millions of people have died as a result of SARS-CoV-2, which was first discovered in China and has since spread globally. Patients with SARS-CoV-2 infection may show a range of symptoms, including fever, coughing, and shortness of breath, or they may show no symptoms at all. To treat COVID-19 symptoms and avoid serious infections, many medications and vaccinations have been employed. However, to entirely eradicate COVID-19 from the world, next-generation vaccine research is required because of the devastating consequences it is having for humanity and every nation’s economy. Scientists are working hard to eradicate this dangerous virus across the world. SARS-CoV-2 has also undergone significant mutation, leading to distinct viral types such as the alpha, beta, gamma, delta, and omicron variants. This has sparked discussion about the effectiveness of current vaccines for the newly formed variants. A proper comparison of these vaccinations is required to compare their efficacy as the number of people immunized against SARS-CoV-2 globally increases. Population-level statistics evaluating the capacity of these vaccines to reduce infection are therefore being developed. In this paper, we analyze the many vaccines on the market in terms of their production process, price, dosage needed, and efficacy. This article also discusses the challenges of achieving herd immunity, the likelihood of reinfection, and the importance of convalescent plasma therapy in reducing infection.
Author Gupta, Sneha
Ganguly, Nirmal Kumar
Rana, Rashmi
Kant, Ravi
Rana, Devinder Singh
Kumra, Tanya
AuthorAffiliation 1 Department of Research , Sir Ganga Ram Hospital , New Delhi , India
2 Department of Nephrology , Sir Ganga Ram Hospital , New Delhi , India
AuthorAffiliation_xml – name: 2 Department of Nephrology , Sir Ganga Ram Hospital , New Delhi , India
– name: 1 Department of Research , Sir Ganga Ram Hospital , New Delhi , India
Author_xml – sequence: 1
  givenname: Rashmi
  surname: Rana
  fullname: Rana, Rashmi
– sequence: 2
  givenname: Ravi
  surname: Kant
  fullname: Kant, Ravi
– sequence: 3
  givenname: Tanya
  surname: Kumra
  fullname: Kumra, Tanya
– sequence: 4
  givenname: Sneha
  surname: Gupta
  fullname: Gupta, Sneha
– sequence: 5
  givenname: Devinder Singh
  surname: Rana
  fullname: Rana, Devinder Singh
– sequence: 6
  givenname: Nirmal Kumar
  surname: Ganguly
  fullname: Ganguly, Nirmal Kumar
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36969857$$D View this record in MEDLINE/PubMed
BookMark eNp9kUtv1DAUhS1UREvpH2CBsmSTwfZN7JgNGo14VKqERIGt5djXravEHpwECX49nkdRywJvbF2f8x3pnufkJKaIhLxkdAXQqTd-e2vyilMOK8Z4C7R9Qs6YEFCrjvGTB-9TcjFNd7QcUApE84ycglBCda08I2_XsVq2zsxYpVhdr79c15v0veZVGMclht9mDmVuoqv8Mi8ZKxcy2t1wekGeejNMeHG8z8m3D--_bj7VV58_Xm7WV7VthJprJ0TPLFimbC85cmEt806CdAC-x4Z74J1SViG1AL2U1nnbU9tgz9B4A-fk8sB1ydzpbQ6jyb90MkHvBynfaJPnYAfULTJQFAQw6BvaOUP7lklRIlA2rXeF9e7A2i79iM5inLMZHkEf_8Rwq2_ST83K9kBSVgivj4Scfiw4zXoMk8VhMBHTMmkuFZO0bVtepK8ehv1Nud9-EXQHgc1pmjJ6bcO833jJDkMJ1buu9b5rvetaH7suVv6P9Z7-H9MfJk-tKg
CitedBy_id crossref_primary_10_3389_fpubh_2024_1386596
crossref_primary_10_1016_j_micres_2023_127504
crossref_primary_10_1002_hsr2_70166
crossref_primary_10_1038_s41598_025_91246_y
crossref_primary_10_1016_j_vaccine_2024_07_047
crossref_primary_10_1016_j_hsr_2023_100127
crossref_primary_10_1016_j_carbpol_2024_122776
crossref_primary_10_1021_acsomega_4c06092
crossref_primary_10_1089_ham_2024_0045
Cites_doi 10.1038/s41591-020-0820-9
10.1016/j.jinf.2021.01.005
10.7326/0003-4819-145-8-200610170-00139
10.1186/s43042-022-00224-w
10.1038/d41586-022-00149-9
10.1159/000513035
10.1128/mBio.02298-16
10.1111/irv.12735
10.1093/infdis/jiu396
10.4155/tde-2020-0035
10.1093/jtm/taac033
10.1208/s12249-021-02058-y
10.1056/NEJMoa2006100
10.1016/j.cmi.2020.11.028
10.1038/s41591-022-01704-7
10.1038/nm1143
10.1016/S0140-6736(21)00675-9
10.1128/cmr.00200-21
10.1016/S0140-6736(21)00298-1
10.1038/s41467-022-32524-5
10.1001/jama.2021.2747
10.1001/jama.2020.1585
10.1056/NEJMoa1211721
10.1093/ve/veac080
10.1136/bmj.o295
10.1016/j.lfs.2020.117839
10.1126/science.abc3517
10.1038/s41586-020-2012-7
10.22092/ari.2021.356147.1791
10.1016/S1473-3099(22)00143-8
10.1038/s41586-020-2008-3
10.1038/s43856-022-00174-9
10.1016/j.nmni.2021.100926
10.3390/vaccines10050817
10.1002/jmv.27281
10.1002/jmv.27789
10.1056/NEJM-oa2108891
10.1016/j.medidd.2021.100114
10.3389/fpubh.2021.818401
10.1007/s42485-020-00052-9
10.1093/toxsci/kfj169
10.1080/22221751.2022.2052358
10.1128/CMR.00072-20
10.1016/S1473-3099(21)00262-0
10.1080/22221751.2022.2030200
10.1038/s41591-020-0995-0
10.1126/science.abi7994
10.1097/CCM.0b013e3181d44c1e
10.2174/2589977513666210611155426
10.1126/science.abd7728
10.1016/j.eclinm.2021.101126
10.1016/S0140-6736(21)00234-8
10.1093/infdis/119.3.282
10.1038/s41591-021-01270-4
10.1101/2022.09.14.22279916
10.1177/2632010X221075584
10.1007/s12038-020-00040-7
10.1001/jama.2020.15543
10.1038/s41591-021-01377-8
10.1371/journal.pone.0264700
10.2174/2211738508999200817163335
10.3201/eid2209.151164
10.1016/j.jinf.2022.03.016
10.1016/j.cmi.2021.11.011
10.1016/s0140-6736(21)00257-9
10.1056/NEJMc2025179
10.1056/NEJMoa2034577
10.1073/pnas.2004168117
10.1099/0022-1317-1-2-175
10.3390/v13040638
10.1016/j.medidd.2021.100086
10.1038/s41586-020-2405-7
10.1016/j.biopha.2022.113522
10.1016/j.cell.2021.02.037
10.1136/jim-2021-002158
10.1016/j.vaccine.2022.02.014
10.1016/j.jinf.2022.01.033
10.1016/j.mayocp.2021.02.008
10.1038/s41591-021-01318-5
10.1038/d41573-020-00073-5
10.1111/j.1600-065X.2010.00980.x
10.3389/fphar.2020.543718
10.1056/NEJMoa2035389
10.3324/haematol.2020.261784
10.1016/j.jare.2020.03.005
10.1093/cid/ciaa1275
10.3389/fmolb.2020.00227
10.1038/s41586-020-2550-z
10.1016/j.micres.2022.127204
10.1016/j.coi.2011.03.008
10.1177/0020764020915212
10.1016/S0140-6736(21)00191-4
10.1038/s41591-020-0843-2
10.1016/j.jconrel.2021.03.043
10.1016/j.ijsu.2022.106654
10.1056/NEJMc2104974
10.1128/CMR.00028-20
10.3201/eid2607.200282
10.1128/JVI.79.2.884-895.2005
10.18632/aging.103795
10.1016/j.cell.2021.04.025
10.1093/cid/cix639
10.1007/s00281-017-0629-x
10.1056/NEJMoa2033700
10.1111/tmi.13383
10.1056/NEJMoa2001017
10.1038/nm1024
10.1016/j.lanepe.2021.100208
10.2139/ssrn.4011905
10.1056/NEJMoa2107659
10.1177/2150132720982752
10.1056/NEJMoa2001316
10.1136/bmj.m3939
10.1056/NEJMoa2113017
10.1111/vox.13091
10.15252/emmm.202216287
10.1111/vox.12940
10.1080/21645515.2022.2065824
ContentType Journal Article
Copyright Copyright © 2023 Rana, Kant, Kumra, Gupta, Rana and Ganguly.
Copyright © 2023 Rana, Kant, Kumra, Gupta, Rana and Ganguly. 2023 Rana, Kant, Kumra, Gupta, Rana and Ganguly
Copyright_xml – notice: Copyright © 2023 Rana, Kant, Kumra, Gupta, Rana and Ganguly.
– notice: Copyright © 2023 Rana, Kant, Kumra, Gupta, Rana and Ganguly. 2023 Rana, Kant, Kumra, Gupta, Rana and Ganguly
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.3389/fphar.2023.1125305
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ (Directory of Open Access Journals)
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

PubMed
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Rana et al
EISSN 1663-9812
ExternalDocumentID oai_doaj_org_article_5e139036313b408da0b51762f3e745fd
PMC10033701
36969857
10_3389_fphar_2023_1125305
Genre Journal Article
Review
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
O5R
O5S
OK1
P2P
PGMZT
RNS
RPM
IAO
IEA
IHR
IHW
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c469t-d66b1c3c19cb72e26cc1fd737d33fbe42f32899c9e0c33b77cdfcb0c4eb1eafa3
IEDL.DBID M48
ISSN 1663-9812
IngestDate Wed Aug 27 01:24:42 EDT 2025
Thu Aug 21 18:38:41 EDT 2025
Fri Jul 11 16:22:08 EDT 2025
Thu Jan 02 22:35:38 EST 2025
Tue Jul 01 02:53:00 EDT 2025
Thu Apr 24 22:57:46 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords COVID-19
herd immunity
convalescent plasma therapy
SARS-CoV-2
reinfection
Pfizer
Moderna
vaccine efficacy
Language English
License Copyright © 2023 Rana, Kant, Kumra, Gupta, Rana and Ganguly.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c469t-d66b1c3c19cb72e26cc1fd737d33fbe42f32899c9e0c33b77cdfcb0c4eb1eafa3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
This article was submitted to Pharmacology of Infectious Diseases, a section of the journal Frontiers in Pharmacology
Milad Zandi, Tehran University of Medical Sciences, Iran
AbdulRahman A. Saied, Independent researcher, Aswan, Egypt
Reviewed by: Deepak Chandran, Amrita Vishwa Vidyapeetham University, India
Edited by: Ranjan K. Mohapatra, Government College of Engineering, India
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fphar.2023.1125305
PMID 36969857
PQID 2791705552
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_5e139036313b408da0b51762f3e745fd
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10033701
proquest_miscellaneous_2791705552
pubmed_primary_36969857
crossref_citationtrail_10_3389_fphar_2023_1125305
crossref_primary_10_3389_fphar_2023_1125305
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-03-09
PublicationDateYYYYMMDD 2023-03-09
PublicationDate_xml – month: 03
  year: 2023
  text: 2023-03-09
  day: 09
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in pharmacology
PublicationTitleAlternate Front Pharmacol
PublicationYear 2023
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Dhama (B25) 2020; 33
(B92) 2022
Goher (B38) 2022; 13
González (B40) 2021; 40
Han (B43) 2020; 14
Juno (B52) 2020; 26
Arabi (B9) 2016; 22
Wang (B122) 2022; 11
Xia (B130) 2020; 324
Shereen (B105) 2020; 24
(B12) 2021
Saied (B98) 2022; 14
Wang (B121) 2020; 323
Burki (B17) 2021; 397
(B126) 2022
Renu (B96) 2020; 255
Xie (B131) 2021; 27
Vokó (B118) 2022; 28
Focosi (B33) 2020; 33
Duan (B27) 2020; 117
Luke (B69) 2010; 38
Zhao (B136) 2021; 13
Mair-Jenkins (B72) 2015; 211
(B88) 2021
Liu (B66) 2011; 239
González (B39) 2022; 70
Amawi (B7) 2020; 11
Torales (B112) 2020; 66
Ewunkem (B30) 2022
Cheng (B22) 2022; 28
Franchini (B37) 2021; 116
Chen (B21) 2020; 12
Zhou (B137) 2021; 184
Libster (B65) 2021; 384
McCallum (B76) 2021; 373
Le Bert (B61) 2020; 584
Hosch (B46) 2022; 9
Kapikian (B53) 1969; 119
Caralis (B18) 2021; 12
Polack (B90) 2020; 383
Sheets (B104) 2006; 91
Zhu (B139) 2020; 382
Focosi (B35) 2021; 116
Colson (B23) 2022; 94
Leung (B62) 2022
Almeida (B6) 1967; 1
Dhawan (B26) 2022; 154
Macdonald (B71) 2022; 2
Lopez Bernal (B68) 2021; 385
Planas (B89) 2021; 27
To (B111) 2021; 73
Gudbjartsson (B41) 2020; 382
Wajnberg (B119); 370
Edouard (B28) 2020
Perotti (B86) 2020; 105
Wu (B129) 2020; 579
(B115) 2021
Peiris (B85) 2004; 10
Stowe (B108) 2021
Channappanavar (B20) 2017; 39
Hill (B45) 2022
Brief (B16) 2020; 7
Janiaud (B49) 2021; 325
Rana (B95) 2020; 11
Wajnberg (B120)
(B83) 2021
Pramod (B91) 2022; 40
Klassen (B56) 2021; 96
Kreier (B57) 2022; 602
Zaki (B135) 2012; 367
Lancet (B59) 2021; 397
Thanh Le (B110) 2020; 19
Islam (B48) 2022; 15
Nao (B80) 2017; 8
Focosi (B34) 2021; 48
Li (B64) 2020; 382
Woo (B128) 2005; 79
Naaber (B79) 2021; 10
Rana (B94) 2022; 265
Jones (B51) 2021; 397
Khoury (B55) 2021; 27
Zhou (B138) 2020; 579
Andersen (B8) 2020; 26
Abu-Raddad (B1) 2021; 385
Agarwal (B2) 2020; 371
(B19) 2021
Bio (B14) 2021
Wong (B127) 2021; 43
El Sahly (B29) 2021; 385
Flaxman (B31) 2020; 584
Aljabali (B5) 2020; 8
Focosi (B36) 2022; 35
Khehra (B54) 2021; 22
Nguyen (B81) 2022; 11
Hall (B42) 2021; 397
B125
B124
Mattiuzzi (B73) 2022; 84
(B50) 2021
Leung (B63) 2020; 26
Breathnach (B15) 2021; 82
Mohapatra (B77) 2022; 18
(B13) 2021
Velavan (B116) 2020; 25
Kuppili (B58) 2021; 76
Nordström (B82) 2022; 22
Baden (B11) 2021; 384
Maulud (B74) 2022; 102
Sapkal (B102) 2022; 29
Yadav (B132) 2022; 84
Florentino (B32) 2022; 13
Mukherjee (B78) 2020; 45
(B87) 2020
Ibarrondo (B47) 2020; 383
Verbeke (B117) 2021; 333
Sardesai (B103) 2011; 23
Waqas (B123) 2020; 7
Uddin (B113) 2021; 13
Salje (B100) 2020; 369
Sanche (B101) 2020; 26
Logunov (B67) 2021; 397
Ali (B3); 43
Lapa (B60) 2022; 10
Heath (B44) 2021; 385
Ramanathan (B93) 2021; 21
Arciuolo (B10) 2017; 65
Yang (B134) 2020; 11
Yahav (B133) 2021; 27
Ali (B4); 10
Sajid (B99) 2022; 17
Paneth (B84) 2022; 376
Rouzbahani (B97) 2022; 23
Sotoodeh Ghorbani (B106) 2022; 94
Deng (B24) 2021; 184
Luke (B70) 2006; 145
(B75) 2021
(B107) 2021
Van Der Hoek (B114) 2004; 10
Tartof (B109) 2022
References_xml – volume: 26
  start-page: 450
  year: 2020
  ident: B8
  article-title: The proximal origin of SARS-CoV-2
  publication-title: Nat. Med.
  doi: 10.1038/s41591-020-0820-9
– volume: 82
  start-page: e11
  year: 2021
  ident: B15
  article-title: Prior COVID-19 significantly reduces the risk of subsequent infection, but reinfections are seen after eight months
  publication-title: J. Infect.
  doi: 10.1016/j.jinf.2021.01.005
– volume: 145
  start-page: 599
  year: 2006
  ident: B70
  article-title: Meta-analysis: Convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment?
  publication-title: Ann. Intern. Med.
  doi: 10.7326/0003-4819-145-8-200610170-00139
– volume: 23
  start-page: 16
  year: 2022
  ident: B97
  article-title: Design of a multi-epitope-based peptide vaccine against the S and N proteins of SARS-COV-2 using immunoinformatics approach
  publication-title: Egypt. J. Med. Hum. Genet.
  doi: 10.1186/s43042-022-00224-w
– volume: 602
  start-page: 19
  year: 2022
  ident: B57
  article-title: Deltacron: The story of the variant that wasn’t
  publication-title: Nature.
  doi: 10.1038/d41586-022-00149-9
– volume: 48
  start-page: 132
  year: 2021
  ident: B34
  article-title: Urgent need to regulate convalescent plasma differently from thawed plasma
  publication-title: Transfus. Med. Hemotherapy.
  doi: 10.1159/000513035
– volume: 8
  start-page: 022988
  year: 2017
  ident: B80
  article-title: Genetic predisposition to acquire a polybasic cleavage site for highly pathogenic avian influenza virus hemagglutinin
  publication-title: MBio.
  doi: 10.1128/mBio.02298-16
– volume: 7
  start-page: 1
  year: 2020
  ident: B16
  article-title: Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom
  publication-title: Epidemiology
– volume: 14
  start-page: 470
  year: 2020
  ident: B43
  article-title: Uncertainties about the transmission routes of 2019 novel coronavirus
  publication-title: Influenza Other Respir. Viruses.
  doi: 10.1111/irv.12735
– volume: 211
  start-page: 80
  year: 2015
  ident: B72
  article-title: The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/jiu396
– volume: 11
  start-page: 245
  year: 2020
  ident: B7
  article-title: COVID-19 pandemic: An overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics
  publication-title: Ther. Deliv.
  doi: 10.4155/tde-2020-0035
– volume: 29
  start-page: taac033
  year: 2022
  ident: B102
  article-title: Immune responses against different variants of SARS-CoV-2 including Omicron following 6 months of administration of heterologous prime-boost COVID-19 vaccine
  publication-title: J. Travel Med.
  doi: 10.1093/jtm/taac033
– volume: 22
  start-page: 172
  year: 2021
  ident: B54
  article-title: Tozinameran (BNT162b2) vaccine: The journey from preclinical research to clinical trials and authorization
  publication-title: Aaps Pharmscitech.
  doi: 10.1208/s12249-021-02058-y
– volume: 382
  start-page: 2302
  year: 2020
  ident: B41
  article-title: Spread of SARS-CoV-2 in the Icelandic population
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2006100
– volume: 27
  start-page: 315
  year: 2021
  ident: B133
  article-title: Definitions for coronavirus disease 2019 re-infection, relapse and PCR re-positivity
  publication-title: Clin. Microbiol. Infect.
  doi: 10.1016/j.cmi.2020.11.028
– volume: 28
  start-page: 486
  year: 2022
  ident: B22
  article-title: Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA. 1 following homologous and heterologous CoronaVac or BNT162b2 vaccination
  publication-title: Nat. Med.
  doi: 10.1038/s41591-022-01704-7
– volume-title: Assessment. Status of COVID-19 vaccines within WHO EUL/PQ evaluation process
  year: 2021
  ident: B14
  article-title: Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process
– volume: 10
  start-page: S88
  year: 2004
  ident: B85
  article-title: Severe acute respiratory syndrome
  publication-title: Nat. Med.
  doi: 10.1038/nm1143
– volume: 397
  start-page: 1459
  year: 2021
  ident: B42
  article-title: SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in england: A large, multicentre, prospective cohort study (SIREN)
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(21)00675-9
– volume: 35
  start-page: e0020021
  year: 2022
  ident: B36
  article-title: COVID-19 convalescent plasma and clinical trials: Understanding conflicting outcomes
  publication-title: Clin. Microbiol. Rev.
  doi: 10.1128/cmr.00200-21
– volume-title: Bharat Biotech
  year: 2021
  ident: B12
– volume: 397
  start-page: 462
  year: 2021
  ident: B17
  article-title: Understanding variants of SARS-CoV-2
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(21)00298-1
– volume: 13
  start-page: 4756
  year: 2022
  ident: B32
  article-title: Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-022-32524-5
– volume: 325
  start-page: 1185
  year: 2021
  ident: B49
  article-title: Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: A systematic review and meta-analysis
  publication-title: Jama.
  doi: 10.1001/jama.2021.2747
– volume: 323
  start-page: 1061
  year: 2020
  ident: B121
  article-title: Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China
  publication-title: Jama.
  doi: 10.1001/jama.2020.1585
– volume: 367
  start-page: 1814
  year: 2012
  ident: B135
  article-title: Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1211721
– year: 2022
  ident: B45
  article-title: The origins and molecular evolution of SARS-CoV-2 lineage B. 1.1. 7 in the UK
  doi: 10.1093/ve/veac080
– volume: 376
  year: 2022
  ident: B84
  article-title: WHO Covid-19 drugs guideline: Reconsider using convalescent plasma
  publication-title: BMJ Br. Med. J.
  doi: 10.1136/bmj.o295
– volume: 255
  start-page: 117839
  year: 2020
  ident: B96
  article-title: Coronaviruses pathogenesis, comorbidities and multi-organ damage–A review
  publication-title: Life Sci.
  doi: 10.1016/j.lfs.2020.117839
– volume: 369
  start-page: 208
  year: 2020
  ident: B100
  article-title: Estimating the burden of SARS-CoV-2 in France
  publication-title: Science.
  doi: 10.1126/science.abc3517
– volume: 579
  start-page: 270
  year: 2020
  ident: B138
  article-title: A pneumonia outbreak associated with a new coronavirus of probable bat origin
  publication-title: Nature.
  doi: 10.1038/s41586-020-2012-7
– volume-title: COVID-19 natural immunity
  ident: B124
– volume: 76
  start-page: 1165
  year: 2021
  ident: B58
  article-title: Consecutive hits of COVID-19 in India: The mystery of plummeting cases and current scenario
  publication-title: Archives Razi Inst.
  doi: 10.22092/ari.2021.356147.1791
– volume: 22
  start-page: 781
  year: 2022
  ident: B82
  article-title: Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: A retrospective, total population cohort study in Sweden
  publication-title: Lancet Infect. Dis.
  doi: 10.1016/S1473-3099(22)00143-8
– volume: 579
  start-page: 265
  year: 2020
  ident: B129
  article-title: A new coronavirus associated with human respiratory disease in China
  publication-title: Nature.
  doi: 10.1038/s41586-020-2008-3
– volume: 2
  start-page: 109
  year: 2022
  ident: B71
  article-title: Affinity of anti-spike antibodies to three major SARS-CoV-2 variants in recipients of three major vaccines
  publication-title: Commun. Med.
  doi: 10.1038/s43856-022-00174-9
– volume: 43
  start-page: 100926
  ident: B3
  article-title: SARS-CoV-2 reinfection in patients negative for immunoglobulin G following recovery from COVID-19
  publication-title: New Microbes New Infect.
  doi: 10.1016/j.nmni.2021.100926
– volume-title: Pfizer
  year: 2020
  ident: B87
– volume: 10
  start-page: 817
  year: 2022
  ident: B60
  article-title: Retention of neutralizing response against SARS-CoV-2 omicron variant in sputnik V-Vaccinated individuals
  publication-title: Vaccines.
  doi: 10.3390/vaccines10050817
– volume: 94
  start-page: 44
  year: 2022
  ident: B106
  article-title: Epidemiologic characteristics of cases with reinfection, recurrence, and hospital readmission due to COVID-19: A systematic review and meta-analysis
  publication-title: J. Med. virology.
  doi: 10.1002/jmv.27281
– volume: 94
  start-page: 3739
  year: 2022
  ident: B23
  article-title: Culture and identification of a “Deltamicron” SARS-CoV-2 in a three cases cluster in southern France
  publication-title: J. Med. Virology.
  doi: 10.1002/jmv.27789
– volume: 385
  start-page: 585
  year: 2021
  ident: B68
  article-title: Effectiveness of covid-19 vaccines against the B. 1.617.2 (delta) variant
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJM-oa2108891
– volume-title: Cdsco
  year: 2021
  ident: B19
– volume: 13
  start-page: 100114
  year: 2022
  ident: B38
  article-title: The Delta variant mutations in the receptor binding domain of SARS-CoV-2 show enhanced electrostatic interactions with the ACE2
  publication-title: Med. drug Discov.
  doi: 10.1016/j.medidd.2021.100114
– volume: 9
  start-page: 818401
  year: 2022
  ident: B46
  article-title: Genomic surveillance enables the identification of co-infections with multiple SARS-CoV-2 lineages in Equatorial Guinea
  publication-title: Front. Public Health
  doi: 10.3389/fpubh.2021.818401
– volume-title: Pfizer
  year: 2021
  ident: B88
– volume: 11
  start-page: 223
  year: 2020
  ident: B95
  article-title: A comprehensive overview of proteomics approach for COVID 19: New perspectives in target therapy strategies
  publication-title: J. Proteins Proteomics
  doi: 10.1007/s42485-020-00052-9
– volume: 91
  start-page: 610
  year: 2006
  ident: B104
  article-title: Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts
  publication-title: Toxicol. Sci.
  doi: 10.1093/toxsci/kfj169
– volume-title: Vaxzevria
  year: 2021
  ident: B115
– volume-title: Coronavirus pandemic (COVID-19)
  year: 2020
  ident: B28
– volume: 11
  start-page: 894
  year: 2022
  ident: B81
  article-title: SARS-CoV-2 reinfection and COVID-19 severity
  publication-title: Emerg. microbes Infect.
  doi: 10.1080/22221751.2022.2052358
– volume: 33
  start-page: 000722
  year: 2020
  ident: B33
  article-title: Convalescent plasma therapy for COVID-19: State of the art
  publication-title: Clin. Microbiol. Rev.
  doi: 10.1128/CMR.00072-20
– volume: 21
  start-page: 1070
  year: 2021
  ident: B93
  article-title: SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity
  publication-title: Lancet Infect. Dis.
  doi: 10.1016/S1473-3099(21)00262-0
– volume: 11
  start-page: 477
  year: 2022
  ident: B122
  article-title: Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies
  publication-title: Emerg. microbes Infect.
  doi: 10.1080/22221751.2022.2030200
– volume: 26
  start-page: 1428
  year: 2020
  ident: B52
  article-title: Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19
  publication-title: Nat. Med.
  doi: 10.1038/s41591-020-0995-0
– volume: 373
  start-page: 648
  year: 2021
  ident: B76
  article-title: SARS-CoV-2 immune evasion by the B. 1.427/B. 1.429 variant of concern
  publication-title: Science.
  doi: 10.1126/science.abi7994
– volume: 38
  start-page: e66
  year: 2010
  ident: B69
  article-title: Hark back: Passive immunotherapy for influenza and other serious infections
  publication-title: Crit. care Med.
  doi: 10.1097/CCM.0b013e3181d44c1e
– volume: 13
  start-page: 184
  year: 2021
  ident: B113
  article-title: Potential drugs for the treatment of COVID-19: Synthesis, brief history and application
  publication-title: Curr. Drug Res. Rev. Former. Curr. Drug Abuse Rev.
  doi: 10.2174/2589977513666210611155426
– ident: B120
  article-title: SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months
  doi: 10.1126/science.abd7728
– volume: 40
  start-page: 101126
  year: 2021
  ident: B40
  article-title: Effectiveness of the first component of gam-COVID-vac (sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: A retrospective cohort study in Argentina
  publication-title: EClinicalMedicine
  doi: 10.1016/j.eclinm.2021.101126
– volume: 397
  start-page: 671
  year: 2021
  ident: B67
  article-title: Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)00234-8
– volume-title: Jcovden
  year: 2021
  ident: B50
– volume: 119
  start-page: 282
  year: 1969
  ident: B53
  article-title: Isolation from man of “avian infectious bronchitis virus-like” viruses (coronaviruses) similar to 229E virus, with some epidemiological observations
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/119.3.282
– volume-title: Precision vaccinations
  year: 2022
  ident: B92
– volume: 43
  start-page: 203
  year: 2021
  ident: B127
  article-title: COVID-19 vaccines and herd immunity: Perspectives, challenges and prospects
  publication-title: Malays. J. pathology.
– volume: 27
  start-page: 620
  year: 2021
  ident: B131
  article-title: Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera
  publication-title: Nat. Med.
  doi: 10.1038/s41591-021-01270-4
– year: 2022
  ident: B62
  article-title: Humoral and cellular immunogenicity and safety of 3 doses of CoronaVac and BNT162b2 in young children and adolescents with kidney diseases
  doi: 10.1101/2022.09.14.22279916
– volume: 15
  start-page: 2632010X221075584
  year: 2022
  ident: B48
  article-title: New coronavirus variants are creating more challenges to global healthcare system: A brief report on the current knowledge
  publication-title: Clin. Pathol.
  doi: 10.1177/2632010X221075584
– volume: 45
  start-page: 68
  year: 2020
  ident: B78
  article-title: Global efforts on vaccines for COVID-19: Since, sooner or later, we all will catch the coronavirus
  publication-title: J. Biosci.
  doi: 10.1007/s12038-020-00040-7
– volume: 324
  start-page: 951
  year: 2020
  ident: B130
  article-title: Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: Interim analysis of 2 randomized clinical trials
  publication-title: Jama.
  doi: 10.1001/jama.2020.15543
– volume: 27
  start-page: 1205
  year: 2021
  ident: B55
  article-title: Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
  publication-title: Nat. Med.
  doi: 10.1038/s41591-021-01377-8
– volume-title: Nuvaxovid
  year: 2021
  ident: B83
– volume: 17
  start-page: e0264700e0264700
  year: 2022
  ident: B99
  article-title: Epitope-based peptide vaccine design and elucidation of novel compounds against 3C like protein of SARS-CoV-2
  publication-title: PLoS One.
  doi: 10.1371/journal.pone.0264700
– volume: 8
  start-page: 323
  year: 2020
  ident: B5
  article-title: COVID-19: Underpinning research for detection, therapeutics, and vaccines development
  publication-title: Pharm. Nanotechnol.
  doi: 10.2174/2211738508999200817163335
– volume-title: Mayoclinic
  year: 2021
  ident: B75
– volume: 22
  start-page: 1554
  year: 2016
  ident: B9
  article-title: Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia
  publication-title: Emerg. Infect. Dis.
  doi: 10.3201/eid2209.151164
– volume: 84
  start-page: 834
  year: 2022
  ident: B132
  article-title: Elevated neutralization of Omicron with sera of COVID-19 recovered and breakthrough cases vaccinated with Covaxin than two dose naïve vaccinees
  publication-title: J. Infect.
  doi: 10.1016/j.jinf.2022.03.016
– volume: 28
  start-page: 398
  year: 2022
  ident: B118
  article-title: Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary—The HUN-ve study
  publication-title: Clin. Microbiol. Infect.
  doi: 10.1016/j.cmi.2021.11.011
– volume: 397
  start-page: 445
  year: 2021
  ident: B59
  article-title: Genomic sequencing in pandemics
  publication-title: Lancet (London, Engl.
  doi: 10.1016/s0140-6736(21)00257-9
– volume-title: WHO
  year: 2022
  ident: B126
– volume: 383
  start-page: 1085
  year: 2020
  ident: B47
  article-title: Rapid decay of anti–SARS-CoV-2 antibodies in persons with mild Covid-19
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMc2025179
– volume: 383
  start-page: 2603
  year: 2020
  ident: B90
  article-title: Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2034577
– volume: 117
  start-page: 9490
  year: 2020
  ident: B27
  article-title: Effectiveness of convalescent plasma therapy in severe COVID-19 patients
  publication-title: Proc. Natl. Acad. Sci.
  doi: 10.1073/pnas.2004168117
– volume: 1
  start-page: 175
  year: 1967
  ident: B6
  article-title: The morphology of three previously uncharacterized human respiratory viruses that grow in organ culture
  publication-title: J. General Virology.
  doi: 10.1099/0022-1317-1-2-175
– volume: 13
  start-page: 638
  year: 2021
  ident: B136
  article-title: Inferring the association between the risk of COVID-19 case fatality and N501Y substitution in SARS-CoV-2
  publication-title: Viruses.
  doi: 10.3390/v13040638
– volume-title: Public health england
  year: 2021
  ident: B108
  article-title: Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B. 1.617. 2) variant
– volume: 10
  start-page: 100086
  ident: B4
  article-title: The new SARS-CoV-2 strain shows a stronger binding affinity to ACE2 due to N501Y mutant
  publication-title: Med. drug Discov.
  doi: 10.1016/j.medidd.2021.100086
– volume: 584
  start-page: 257
  year: 2020
  ident: B31
  article-title: Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe
  publication-title: Nature.
  doi: 10.1038/s41586-020-2405-7
– volume: 154
  start-page: 113522
  year: 2022
  ident: B26
  article-title: Omicron variant (B. 1.1. 529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2022.113522
– volume: 184
  start-page: 2348
  year: 2021
  ident: B137
  article-title: Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera
  publication-title: Cell.
  doi: 10.1016/j.cell.2021.02.037
– volume: 70
  start-page: 1258
  year: 2022
  ident: B39
  article-title: Timing of convalescent plasma administration and 28-day mortality in COVID-19 pneumonia
  publication-title: J. Investigative Med.
  doi: 10.1136/jim-2021-002158
– volume: 40
  start-page: 3294
  year: 2022
  ident: B91
  article-title: Effectiveness of Covishield vaccine in preventing Covid-19–A test-negative case-control study
  publication-title: Vaccine.
  doi: 10.1016/j.vaccine.2022.02.014
– volume: 84
  start-page: 722
  year: 2022
  ident: B73
  article-title: COVID-19 vaccines efficacy in preventing or limiting SARS-CoV-2 infections
  publication-title: J. Infect.
  doi: 10.1016/j.jinf.2022.01.033
– volume: 96
  start-page: 1262
  year: 2021
  ident: B56
  article-title: The effect of convalescent plasma therapy on mortality among patients with COVID-19: Systematic review and meta-analysis
  publication-title: Mayo Clin. Proc.
  doi: 10.1016/j.mayocp.2021.02.008
– volume: 27
  start-page: 917
  year: 2021
  ident: B89
  article-title: Sensitivity of infectious SARS-CoV-2 B. 1.1. 7 and B. 1.351 variants to neutralizing antibodies
  publication-title: Nat. Med.
  doi: 10.1038/s41591-021-01318-5
– volume: 19
  start-page: 305
  year: 2020
  ident: B110
  article-title: The COVID-19 vaccine development landscape
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/d41573-020-00073-5
– volume: 239
  start-page: 62
  year: 2011
  ident: B66
  article-title: DNA vaccines: An historical perspective and view to the future
  publication-title: Immunol. Rev.
  doi: 10.1111/j.1600-065X.2010.00980.x
– volume: 11
  start-page: 543718
  year: 2020
  ident: B134
  article-title: Hydrogen: A potential new adjuvant therapy for COVID-19 patients
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2020.543718
– volume: 384
  start-page: 403
  year: 2021
  ident: B11
  article-title: Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2035389
– volume: 370
  start-page: 1227
  ident: B119
  article-title: Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
  publication-title: Science.
  doi: 10.1126/science.abd7728
– volume: 105
  start-page: 2834
  year: 2020
  ident: B86
  article-title: Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial
  publication-title: Haematologica.
  doi: 10.3324/haematol.2020.261784
– volume-title: Mounting evidence suggests Sputnik COVID vaccine is safe and effective
  year: 2021
  ident: B13
– volume: 24
  start-page: 91
  year: 2020
  ident: B105
  article-title: COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses
  publication-title: J. Adv. Res.
  doi: 10.1016/j.jare.2020.03.005
– volume: 73
  start-page: e2946
  year: 2021
  ident: B111
  article-title: Coronavirus disease 2019 (COVID-19) re-infection by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain confirmed by whole genome sequencing
  publication-title: Clin. Infect. Dis.
  doi: 10.1093/cid/ciaa1275
– volume: 7
  start-page: 227
  year: 2020
  ident: B123
  article-title: Determine the potential epitope based peptide vaccine against novel SARS-CoV-2 targeting structural proteins using immunoinformatics approaches
  publication-title: Front. Mol. Biosci.
  doi: 10.3389/fmolb.2020.00227
– volume: 584
  start-page: 457
  year: 2020
  ident: B61
  article-title: SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
  publication-title: Nature.
  doi: 10.1038/s41586-020-2550-z
– volume: 265
  start-page: 127204
  year: 2022
  ident: B94
  article-title: Omicron variant: Current insights and future directions
  publication-title: Microbiol. Res.
  doi: 10.1016/j.micres.2022.127204
– volume: 23
  start-page: 421
  year: 2011
  ident: B103
  article-title: Electroporation delivery of DNA vaccines: Prospects for success
  publication-title: Curr. Opin. Immunol.
  doi: 10.1016/j.coi.2011.03.008
– volume: 66
  start-page: 317
  year: 2020
  ident: B112
  article-title: The outbreak of COVID-19 coronavirus and its impact on global mental health
  publication-title: Int. J. Soc. psychiatry.
  doi: 10.1177/0020764020915212
– volume: 397
  start-page: 642
  year: 2021
  ident: B51
  article-title: Sputnik V COVID-19 vaccine candidate appears safe and effective
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(21)00191-4
– volume: 26
  start-page: 676
  year: 2020
  ident: B63
  article-title: Respiratory virus shedding in exhaled breath and efficacy of face masks
  publication-title: Nat. Med.
  doi: 10.1038/s41591-020-0843-2
– volume: 333
  start-page: 511
  year: 2021
  ident: B117
  article-title: The dawn of mRNA vaccines: The COVID-19 case
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2021.03.043
– volume-title: WHO
  ident: B125
– volume: 102
  start-page: 106654
  year: 2022
  ident: B74
  article-title: Deltacron: Apprehending a new phase of the COVID-19 pandemic
  publication-title: Int. J. Surg. Lond. Engl.
  doi: 10.1016/j.ijsu.2022.106654
– volume: 385
  start-page: 187
  year: 2021
  ident: B1
  article-title: Effectiveness of the BNT162b2 covid-19 vaccine against the B. 1.1. 7 and B. 1.351 variants
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMc2104974
– volume: 33
  start-page: 000288
  year: 2020
  ident: B25
  article-title: Coronavirus disease 2019–COVID-19
  publication-title: Clin. Microbiol. Rev.
  doi: 10.1128/CMR.00028-20
– year: 2022
  ident: B30
  article-title: An overview of COVID-19 pandemic: Emphasis on vaccines and unvaccinated
  publication-title: ScienceOpen
– volume: 26
  start-page: 1470
  year: 2020
  ident: B101
  article-title: High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2
  publication-title: Emerg. Infect. Dis.
  doi: 10.3201/eid2607.200282
– volume: 79
  start-page: 884
  year: 2005
  ident: B128
  article-title: Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia
  publication-title: J. virology.
  doi: 10.1128/JVI.79.2.884-895.2005
– volume-title: Spikevax
  year: 2021
  ident: B107
– volume: 12
  start-page: 16675
  year: 2020
  ident: B21
  article-title: Clinical course and risk factors for recurrence of positive SARS-CoV-2 RNA: A retrospective cohort study from wuhan, China
  publication-title: Aging (Albany NY).
  doi: 10.18632/aging.103795
– volume: 184
  start-page: 3426
  year: 2021
  ident: B24
  article-title: Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant
  publication-title: Cell.
  doi: 10.1016/j.cell.2021.04.025
– volume: 65
  start-page: 1843
  year: 2017
  ident: B10
  article-title: Effectiveness of measles vaccination and immune globulin post-exposure prophylaxis in an outbreak setting—New York city, 2013
  publication-title: Clin. Infect. Dis.
  doi: 10.1093/cid/cix639
– volume: 39
  start-page: 529
  year: 2017
  ident: B20
  article-title: Pathogenic human coronavirus infections: Causes and consequences of cytokine storm and immunopathology
  publication-title: Seminars Immunopathol.
  doi: 10.1007/s00281-017-0629-x
– volume: 384
  start-page: 610
  year: 2021
  ident: B65
  article-title: Early high-titer plasma therapy to prevent severe covid-19 in older adults
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2033700
– volume: 25
  start-page: 278
  year: 2020
  ident: B116
  article-title: The COVID-19 epidemic
  publication-title: Trop. Med. Int. health.
  doi: 10.1111/tmi.13383
– volume: 382
  start-page: 727
  year: 2020
  ident: B139
  article-title: A novel coronavirus from patients with pneumonia in China, 2019
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2001017
– volume: 10
  start-page: 368
  year: 2004
  ident: B114
  article-title: Identification of a new human coronavirus
  publication-title: Nat. Med.
  doi: 10.1038/nm1024
– volume: 10
  start-page: 100208
  year: 2021
  ident: B79
  article-title: Dynamics of antibody response to BNT162b2 vaccine after six months: A longitudinal prospective study
  publication-title: Lancet Regional Health-Europe
  doi: 10.1016/j.lanepe.2021.100208
– volume-title: BNT162b2 (Pfizer–Biontech) mRNA COVID-19 vaccine against omicron-related hospital and emergency department admission in a large US health system: A test-negative design
  year: 2022
  ident: B109
  doi: 10.2139/ssrn.4011905
– volume: 385
  start-page: 1172
  year: 2021
  ident: B44
  article-title: Safety and efficacy of NVX-CoV2373 Covid-19 vaccine
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2107659
– volume: 12
  start-page: 2150132720982752
  year: 2021
  ident: B18
  article-title: Case reports of COVID 19 recurrence
  publication-title: J. Prim. care & community health
  doi: 10.1177/2150132720982752
– volume: 382
  start-page: 1199
  year: 2020
  ident: B64
  article-title: Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2001316
– volume: 371
  start-page: m3939
  year: 2020
  ident: B2
  article-title: Convalescent plasma in the management of moderate Covid-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID trial)
  publication-title: Bmj
  doi: 10.1136/bmj.m3939
– volume: 385
  start-page: 1774
  year: 2021
  ident: B29
  article-title: Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2113017
– volume: 116
  start-page: 935
  year: 2021
  ident: B35
  article-title: COVID-19 convalescent plasma therapy: Hit fast, hit hard!
  publication-title: Vox Sang.
  doi: 10.1111/vox.13091
– volume: 14
  start-page: e16287
  year: 2022
  ident: B98
  article-title: Strengthening vaccines and medicines manufacturing capabilities in africa: Challenges and perspectives
  publication-title: EMBO Mol. Med.
  doi: 10.15252/emmm.202216287
– volume: 116
  start-page: 136
  year: 2021
  ident: B37
  article-title: Operational protocol for donation of anti-COVID-19 convalescent plasma in Italy
  publication-title: Vox Sang.
  doi: 10.1111/vox.12940
– volume: 18
  start-page: 2065824
  year: 2022
  ident: B77
  article-title: Need of booster vaccine doses to counteract the emergence of SARS-CoV-2 variants in the context of the omicron variant and increasing COVID-19 cases: An update
  publication-title: Hum. Vaccines Immunother.
  doi: 10.1080/21645515.2022.2065824
SSID ssj0000399364
Score 2.357093
SecondaryResourceType review_article
Snippet Millions of people have died as a result of SARS-CoV-2, which was first discovered in China and has since spread globally. Patients with SARS-CoV-2 infection...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1125305
SubjectTerms convalescent plasma therapy
COVID-19
herd immunity
Pharmacology
reinfection
SARS-CoV-2
vaccine efficacy
SummonAdditionalLinks – databaseName: DOAJ (Directory of Open Access Journals)
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlp15K33VfqFByaUQs62X1tg0NodASmqTkJqSRTALBuzS7h_z7aiRns1tKe-nVlvHwzWgeSPMNIe9Tbz2AisxKKZnUQ8t6LTnjXielktBJYIPz12_66Ex-OVfnG6O-8E5YpQeuwO2rlHMUPG3kIsi2j74NiucdPIhkpBoiet8c8zaKqeKDMe5qWbtkchVm94fFhUf-z05g14wSOK9uIxIVwv4_ZZm_X5bciD6HD8mDKW2ksyruI3IvjY_J7nHlnb7Zo6d3bVTXe3SXHt8xUt88IR9nI10tsLan85GezL6fsIP5D9bRy9IdUjsxqR8jrRQjtAY6tMin5Ozw8-nBEZuGJjDIle6SRa0DBwHcQjBd6jQAH6IRJgoxhCQzcFhjgU0tCBGMgThAaEFmp5384MUzsjPOx_SCUC115EFFCBZk3rtBxBzQI-SMzOdMQTSE3wLoYGIUx8EWVy5XFgi6K6A7BN1NoDfkw_qbReXT-OvqT6iX9Urkwi4PsoW4yULcvyykIe9utery3sEDET-m-eradcYWNiHVNeR51fL6Vzjn0PbKNKTf0v-WLNtvxsuLws_NcUCeafnL_yH9K3IfESnX3uxrsrP8uUpvch60DG-Lyf8C1I4Ejg
  priority: 102
  providerName: Directory of Open Access Journals
Title An update on SARS-CoV-2 immunization and future directions
URI https://www.ncbi.nlm.nih.gov/pubmed/36969857
https://www.proquest.com/docview/2791705552
https://pubmed.ncbi.nlm.nih.gov/PMC10033701
https://doaj.org/article/5e139036313b408da0b51762f3e745fd
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELaqcuGCeBMolZFQL9QQx68YCaGloqqQiiraRb1ZfoVWqpLtPiT23-NxslsWFcQ1ceJkxuNvxvZ8g9DrWGvrvQhEc84Jl01JaskpoVZGISKTkUGC8_FXeTTmX87F-RZalTsaBDi7NbSDelLj6dXbn9fLj8ngP0DEmfD2XTO5sEDtWTFIiBEMKE3vJGRSUNHgeHD388wMaJwZpWgCWqITuPV5NH95zQZWZUr_2_zQP49T_oZPh_fRvcGxxKN-JDxAW7F9iPZOembq5T4-u0m0mu3jPXxyw1m9fITej1q8mED0j7sWn46-nZKD7jup8GXOH-lzNbFtA-5JSHAPhTBmH6Px4eezgyMylFUgPsXCcxKkdNQzT7V3qoqV9J42QTEVGGtc5FXDIArzOpaeMaeUD413pedpWo-2sewJ2m67Nj5DWHIZqBPBO-15sm7HQoL84JPPZpMvwQpEVwI0fuAch9IXVybFHiB0k4VuQOhmEHqB3qyfmfSMG_9s_Qn0sm4JbNn5Qjf9YQbjMyImPxd2rClzvKyDLZ2gCQUaFhUXTSjQq5VWTbIu2DKxbewWM1MpnfmGRFWgp72W111BJURdC1WgekP_G9-yeae9vMgM3hRK6KmSPv-Pjl-gu_DD-dyb3kHb8-kivkyO0Nzt5gWE3TzGfwGRtAYJ
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=An+update+on+SARS-CoV-2+immunization+and+future+directions&rft.jtitle=Frontiers+in+pharmacology&rft.au=Rana%2C+Rashmi&rft.au=Kant%2C+Ravi&rft.au=Kumra%2C+Tanya&rft.au=Gupta%2C+Sneha&rft.date=2023-03-09&rft.issn=1663-9812&rft.eissn=1663-9812&rft.volume=14&rft.spage=1125305&rft_id=info:doi/10.3389%2Ffphar.2023.1125305&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-9812&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-9812&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-9812&client=summon